Inhibition of Focal Adhesion Kinase Decreases Tumor Growth in Human Neuroblastoma

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2010 Feb 18

PMID 20160475

Citations 45

Authors

Elizabeth A Beierle

Xiaojie Ma

Jerry Stewart

Carl Nyberg

Angelica Trujillo

William G Cance

Vita M Golubovskaya

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood. Focal adhesion kinase (FAK) is an intracellular kinase that regulates both cellular adhesion and apoptosis. FAK is overexpressed in a number of human tumors including neuroblastoma. Previously, we have shown that the MYCN oncogene, the primary adverse prognostic indicator in neuroblastoma, regulates the expression of FAK in neuroblastoma. In this study, we have examined the effects of FAK inhibition upon neuroblastoma using a small molecule [1,2,4,5-benzenetetraamine tetrahydrochloride (Y15)] to inhibit FAK expression and the phosphorylation of FAK at the Y397 site. Utilizing both non-isogenic and isogenic MYCN(+)/MYCN(-) neuroblastoma cell lines, we found that Y15 effectively diminished phosphorylation of the Y397 site of FAK. Treatment with Y15 resulted in increased detachment, decreased cell viability and increased apoptosis in the neuroblastoma cell lines. We also found that the cell lines with higher MYCN are more sensitive to Y15 treatment than their MYCN negative counterparts. In addition, we have shown that treatment with Y15 in vivo leads to less tumor growth in nude mouse xenograft models, again with the greatest effects seen in MYCN(+) tumor xenografts. The results of the current study suggest that FAK and phosphorylation at the Y397 site plays a role in neuroblastoma cell survival, and that the FAK Y397 phosphorylation site is a potential therapeutic target for this childhood tumor.

Citing Articles

Effect of napabucasin and doxorubicin via the Jak2/Stat3 signaling pathway in suppressing the proliferation of neuroblastoma cells.

Unlu I, Tuncer M, Ozdemir I Acta Cir Bras. 2024; 39:e396624.

PMID: 39356934 PMC: 11441154. DOI: 10.1590/acb396624.

Cancer cells inhibition by cationic carbon dots targeting the cellular nucleus.

Chen J, Li F, Gu J, Zhang X, Bartoli M, Domena J J Colloid Interface Sci. 2023; 637:193-206.

PMID: 36701865 PMC: 9957951. DOI: 10.1016/j.jcis.2023.01.086.

Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.

Musumeci F, Cianciusi A, DAgostino I, Grossi G, Carbone A, Schenone S Molecules. 2021; 26(23).

PMID: 34885651 PMC: 8658969. DOI: 10.3390/molecules26237069.

FAK Inhibition Attenuates Corneal Fibroblast Differentiation In Vitro.

Yeung V, Sriram S, Tran J, Guo X, Hutcheon A, Zieske J Biomolecules. 2021; 11(11).

PMID: 34827680 PMC: 8616004. DOI: 10.3390/biom11111682.

EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth.

Bownes L, Williams A, Marayati R, Stafman L, Markert H, Quinn C PLoS One. 2021; 16(3):e0246244.

PMID: 33690617 PMC: 7942994. DOI: 10.1371/journal.pone.0246244.

References

Schaller M, Hildebrand J, Shannon J, Fox J, Vines R, Parsons J . Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994; 14(3):1680-8. PMC: 358526. DOI: 10.1128/mcb.14.3.1680-1688.1994. View

Han E, McGonigal T, Wang J, Giranda V, Luo Y . Functional analysis of focal adhesion kinase (FAK) reduction by small inhibitory RNAs. Anticancer Res. 2005; 24(6):3899-905. View

Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks S, Kasahara T . Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem. 2000; 275(21):16309-15. DOI: 10.1074/jbc.275.21.16309. View

Weiner T, Liu E, Craven R, Cance W . Expression of focal adhesion kinase gene and invasive cancer. Lancet. 1993; 342(8878):1024-5. DOI: 10.1016/0140-6736(93)92881-s. View

Hanks S, Polte T . Signaling through focal adhesion kinase. Bioessays. 1997; 19(2):137-45. DOI: 10.1002/bies.950190208. View

Frisch S, Vuori K, Ruoslahti E . Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996; 134(3):793-9. PMC: 2120934. DOI: 10.1083/jcb.134.3.793. View

Chen H, Guan J . Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1994; 91(21):10148-52. PMC: 44975. DOI: 10.1073/pnas.91.21.10148. View

Judson P, He X, Cance W, Van Le L . Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer. 1999; 86(8):1551-6. DOI: 10.1002/(sici)1097-0142(19991015)86:6<1551::aid-cncr23>3.0.co;2-p. View

Golubovskaya V, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D . A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem. 2008; 51(23):7405-16. PMC: 2662449. DOI: 10.1021/jm800483v. View

10.

Roberts W, Ung E, Whalen P, Cooper B, Hulford C, Autry C . Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res. 2008; 68(6):1935-44. DOI: 10.1158/0008-5472.CAN-07-5155. View

11.

Halder J, Lin Y, Merritt W, Spannuth W, Nick A, Honda T . Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007; 67(22):10976-83. DOI: 10.1158/0008-5472.CAN-07-2667. View

12.

Zhu X, Wimmer K, Kuick R, Lamb B, Motyka S, Jasty R . N-myc modulates expression of p73 in neuroblastoma. Neoplasia. 2002; 4(5):432-9. PMC: 1564122. DOI: 10.1038/sj.neo.7900255. View

13.

Owens L, Xu L, Dent G, Yang X, Sturge G, Craven R . Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol. 1996; 3(1):100-5. DOI: 10.1007/BF02409059. View

14.

Xu L, Yang X, Craven R, Cance W . The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ. 1998; 9(12):999-1005. View

15.

Weiner T, Liu E, Craven R, Cance W . Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. Ann Surg Oncol. 1994; 1(1):18-27. DOI: 10.1007/BF02303537. View

16.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

17.

Lipinski C, Tran N, Menashi E, Rohl C, Kloss J, Bay R . The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia. 2005; 7(5):435-45. PMC: 1501165. DOI: 10.1593/neo.04712. View

18.

Xu L, Yang X, Bradham C, Brenner D, Baldwin Jr A, Craven R . The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem. 2000; 275(39):30597-604. DOI: 10.1074/jbc.M910027199. View

19.

Kasahara T, Koguchi E, Funakoshi M, Aizu-Yokota E, Sonoda Y . Antiapoptotic action of focal adhesion kinase (FAK) against ionizing radiation. Antioxid Redox Signal. 2002; 4(3):491-9. DOI: 10.1089/15230860260196290. View

20.

Slack-Davis J, Martin K, Tilghman R, Iwanicki M, Ung E, Autry C . Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007; 282(20):14845-52. DOI: 10.1074/jbc.M606695200. View